Finding 3202 (2022-001)

Significant Deficiency Repeat Finding
Requirement
C
Questioned Costs
-
Year
2022
Accepted
2023-12-04
Audit: 5226
Organization: The Scintillon Institute (CA)
Auditor: Leaf & Cole LLP

AI Summary

  • Core Issue: The Institute drew down funds beyond the recommended three-day period, delaying payments.
  • Impacted Requirements: Non-compliance with cash management guidelines under 2 CFR 215.22.
  • Recommended Follow-up: Enhance cash management policies to ensure timely fund transfers and align with compliance standards.

Finding Text

2022‐001: Cash Management – Research and Development Cluster Condition Funds were drawn down by the Institute in excess of the three‐day period recommended by its funding agency, and did not minimize the time elapsing between the transfers of funds from the grantor to the issue of payment by the recipient during the year ended December 31, 2022. Criteria Cash management under 2 CFR 215.22 states that payment methods shall minimize the time elapsing between the transfers of funds from the grantor to the issue of payment by the recipient. Cause The Institute’s preparation and review procedures over the draw‐down of funds were insufficient to minimize the time elapsing between the transfers of funds from the grantor to the issue of payments by the Institute. Effect The Institute was not in compliance with the cash management compliance requirements stated in 2 CFR 215.22 during the year. Recommendation The Institute should improve policies and procedures regarding cash management. This should include the procedure for calculating the allowable cash draw for actual immediate cash needs for expenses to be paid within the three‐day period, in order to minimize the time elapsing between the transfer of funds from the grantor to the issue of payment by the recipient to cover operating cash flow needs.

Categories

Cash Management

Other Findings in this Audit

  • 3193 2022-001
    Significant Deficiency Repeat
  • 3194 2022-001
    Significant Deficiency Repeat
  • 3195 2022-001
    Significant Deficiency Repeat
  • 3196 2022-001
    Significant Deficiency Repeat
  • 3197 2022-001
    Significant Deficiency Repeat
  • 3198 2022-001
    Significant Deficiency Repeat
  • 3199 2022-001
    Significant Deficiency Repeat
  • 3200 2022-001
    Significant Deficiency Repeat
  • 3201 2022-001
    Significant Deficiency Repeat
  • 3203 2022-001
    Significant Deficiency Repeat
  • 3204 2022-001
    Significant Deficiency Repeat
  • 579635 2022-001
    Significant Deficiency Repeat
  • 579636 2022-001
    Significant Deficiency Repeat
  • 579637 2022-001
    Significant Deficiency Repeat
  • 579638 2022-001
    Significant Deficiency Repeat
  • 579639 2022-001
    Significant Deficiency Repeat
  • 579640 2022-001
    Significant Deficiency Repeat
  • 579641 2022-001
    Significant Deficiency Repeat
  • 579642 2022-001
    Significant Deficiency Repeat
  • 579643 2022-001
    Significant Deficiency Repeat
  • 579644 2022-001
    Significant Deficiency Repeat
  • 579645 2022-001
    Significant Deficiency Repeat
  • 579646 2022-001
    Significant Deficiency Repeat

Programs in Audit

ALN Program Name Expenditures
93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research $642,802
93.837 Cardiovascular Diseases Research $469,275
93.866 Aging Research $90,391
93.310 Trans-Nih Research Support $87,404
93.859 Biomedical Research and Research Training $72,204
93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders $28,214
93.855 Allergy, Immunology and Transplantation Research $15,987
93.395 Cancer Treatment Research $10,274